International Researchers Identify Hepatitis C Clinical Trial Drug as Potential Breakthrough Treatment for Hepatitis E Virus

International researchers find that the Hepatitis C drug bemnifosbuvir effectively stops Hepatitis E replication, offering hope for a specific cure.

By: AXL Media

Published: Mar 23, 2026, 6:39 AM EDT

Source: Information for this report was sourced from [Ruhr-Universitaet-Bochum]

Repurposing Existing Antivirals for Neglected Viral Pathogens

The search for an effective treatment against the Hepatitis E virus (HEV) has led an international research coalition to a promising candidate currently undergoing clinical trials for Hepatitis C. Scientists from Ruhr University Bochum, Heidelberg University, and Peking University utilized a specialized library of approximately 500 synthetic molecules to identify compounds capable of disrupting viral growth. According to Dr. Mara Klöhn of Ruhr University Bochum, these nucleotide analogues act as "false building blocks" that mimic the genetic material of the virus, effectively halting its ability to reproduce within the host's system.

Innovative Screening Methods and Cellular Validation

To pinpoint the efficacy of bemnifosbuvir, the research team developed a novel reporter virus equipped with a fluorescent molecule. By infecting cell cultures with this modified Hepatitis E strain and introducing various chemical candidates, investigators were able to visually track viral activity. Jungen Hu from Heidelberg University reported that bemnifosbuvir successfully inhibited the replication process while ensuring the treated cells remained healthy. This breakthrough provides a clear mechanical understanding of how the drug interacts with the virus's life cycle, offering a targeted approach to a disease that has long lacked specific medical intervention.

Success in Preclinical Animal Models and Inflammation Control

Following the successful cellular trials, researchers in China conducted animal experiments to verify the substance's performance in complex biological systems. These tests confirmed that bemnifosbuvir not only stops the virus from spreading but also actively reduces liver inflammation, a primary symptom of acute HEV infection. If the ongoing clinical trials for its primary indication in Hepatitis C are successful, the research team anticipates that the drug could be utilized as an off-label treatment for Hepatitis E in the near future, providing a much-needed tool for clinicians worldwide.